EDGAR Filing Documents for 0001654954-18-001758

Form 8-K - Current report:

SEC Accession No. 0001654954-18-001758

Filing Date

2018-02-21

Accepted

2018-02-21 17:00:20

Documents

Period of Report

2018-02-14

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	CURRENT REPORT	gtbp_8k.htm	8-K	42770
2	EXECUTIVE EMPLOYMENT AGREEMENT	gtbp_ex101.htm	EX-10.1	96946
3	AMENDMENT TO THE EMPLOYMENT AGREEMENT	gtbp_ex102.htm	EX-10.2	18714
4	CONSULTANT AGREEMENT	gtbp_ex103.htm	EX-10.3	98498
5	PRESS RELEASE	gtbp_ex991.htm	EX-99.1	14997
	Complete submission text file	0001654954-18-001758.txt		273650

Mailing Address 1825 K STREET SUITE 510 WASHINGTON, D.C. DC 33602

Business Address 1825 K STREET SUITE 510 WASHINGTON, D.C. DC 33602 (800) 304-9888

GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)